Antidepressants and cognitive impairment in the elderly

Journal of Clinical Psychiatry

Volumn 57, Issue SUPPL. 5, 1996, Pages 38-44

  Oxman, Thomas E ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; MONOAMINE OXIDASE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

AGED; COGNITIVE DEFECT; DEPRESSION; DISABILITY; DRUG CHOICE; DRUG EFFECT; GERIATRIC PATIENT; GERONTOPSYCHIATRY; HUMAN; PRIORITY JOURNAL; REVIEW;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CHILD; CHOLINERGIC ANTAGONISTS; COGNITION DISORDERS; DELIRIUM; DEPRESSIVE DISORDER; HUMANS; MIDDLE AGED; MONOAMINE OXIDASE INHIBITORS; RECEPTORS, NEUROTRANSMITTER; SEROTONIN UPTAKE INHIBITORS; SIGNAL TRANSDUCTION;

EID: 0030013434     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (59)

1. Schaie KW. The optimization of cognitive functioning in old age: predictions based on cohort-sequential and longitudinal data. In: Baltes PB, Baltes MM, eds. Successful Aging. Cambridge, UK: Cambridge University Press; 1990:94-117
2. Rowe JW, Wang S. The biology and physiology of aging. In: Rowe JW, Besdine RW, eds. Geriatric Medicine. 2nd ed. Boston, Mass: Little, Brown; 1988:12-22
3. Miller WR. Psychological deficit in depression. Psychol Bull 1975;82: 238-260
4. Wesnes KA, Simpson PM, Christmas L, et al. The effects of modobemide on cognition. J Neural Transm 1989;28(suppl):91-102
5. Sternberg DE, Jarvik LE. Memory functions in depression. Arch Gen Psychiatry 1976;33:219-224
6. Kendrick DC, Moyes AC. Activity, depression, medication and performance on the Revised Kendrick Battery. Br J Soc Clin Psychol 1979;18: 341-350
7. Siegfried KR, Jansen W, Pahnke K. Cognitive dysfunction in depression: difference between depressed and non-depressed elderly patients and differential cognitive effects of nomifensine. Drug Dev Res 1984;4:533-553
8. Emery VO, Oxman TE. Update on the dementia spectrum of depression. Am J Psychiatry 1992;149:305-317
9. Massman PJ, Butters NM, Delis DC. Some comparisons of the verbal learning deficits in Alzheimer dementia, Huntington disease, and depression. In: Emery VOB, Oxman TE, eds. Dementia Presentations, Differential Diagnosis, and Nosology. Baltimore, Md: Johns Hopkins University Press; 1994:232-248
10. Lampig DL, Spring B, Gelenberg AJ. Effects of two antidepressants on memory performance in depressed outpatients: a double-blind study. Psychopharmacology (Berl) 1984;84:254-261
11. Siegfried K. Cognitive symptoms in late-life depression and their treatment. J Affect Disord 1985;1(suppl):S33-S40
12. Weckowicz TE, Nutter RW, Cruise DG, et al. Speed in test performance in relation to depressive illness and age. Can Psychiatr Assoc J 1972;17: 241-250
13. Fudge JL, Perry PJ, Garvey MJ, et al. Fluoxetine versus trazodone. J Affect Disord 1990;18:275-280
14. Rabins P, Merchant A, Nestadt G. Criteria for diagnosing reversible dementia caused by depression: validation by 2-year follow-up. Br J Psychiatry 1984;144:488-492
15. Reifler BV, Ten L, Raskind M, et al. Double-blind trial of imipramine in Alzheimer's disease patients with and without depression. Am J Psychiatry 1989;146:45-49
16. Davies RK, Tucker GJ, Harrow M, et al, Confusional episodes and antidepressant medication. AmJ Psychiatry 1971;128:127-131
17. Branconnier RJ, Cole JO. Effects of acute administration of trazodone and amitriptyline on cognition, cardiovascular function and salivation in the normal geriatric subject. J Clin Psychopharmacol 1981;1:82S-88S
18. Oxman TE. Delayed recall: demented, depressed, or treated? Lancet 1994; 344:213-214
19. Richelson E. Antimuscarinic and other receptor blocking properties of antidepressants. Mayo Clin Proc 1983;58:40-46
20. Deutsch JA. Physiology of acetylcholine in learning and memory. In: Barbeau A, Growdon JH, Wurtman RJ, eds. Nutrition and the Brain. New York, NY: Raven Press; 1979:343-350
21. Wesnes K, Anand R, LorscheidT. Potential of moclobemide to improve cerebral insufficiency identified using a scopolamine model of aging and dementia. Acta Psychiatr Scand 1990;82(suppl 360):71-72
22. Sunderland T, Weingartner H, Cohen RM, et al. Low-dose oral lorazepam administration in Alzheimer subjects and age-matched controls. Psychopharmacology (Berl) 1989;99:129-133
23. Sakulsripong M, Curran HV, Lader M. Amitriptyline versus trazodone. Eur J Clin Pharmacol 1991;40:43-48
24. Lamy PP, Salzman C, Nevis Olesen J. Drug prescribing patterns, risks, and compliance guidelines. In: Salzman C, ed. Clinical Geriatric Psychopharmacology. 2nd ed. Baltimore, Md: Williams & Wilkins; 1992:15-37
25. Alexopoulos GS. Treatment of depression. In: Salzman C, ed. Clinical Geriatric Psychopharmacology. 2nd ed. Baltimore, Md: Williams & Wilkins; 1992:137-174
26. Beers M, Avorn J, Soumerai SB, et al. Psychoactive medication use in intermediate-care facility residents. JAMA 1988;260:3016-3020
27. Vestal RE, Cusack BJ. Pharmacology and aging. In: Schneider EL, Rowe JW, eds. Handbook of the Biology of Aging. 3rd ed. San Diego, Calif: Academic Press; 1990:349-383
28. Tune L, Carr S, Hoag E, et al. Anticholinergic effects of drugs commonly prescribed for the elderly: potential means for assessing risk of delirium. Am J Psychiatry 1992;149:1393-1394
29. Abernathy DR. Psychotropic drugs and the aging process: pharmacokinetics and pharmacodynamics. In: Salzman C, ed. Clinical Geriatric Psychopharmacology. 2nd ed. Baltimore, Md: Williams & Wilkins; 1992:61-76
30. Zemishlany Z, Thorne AE. Anticholinergic challenge and cognitive functions: a comparison between young and elderly normal subjects. Isr J Psychiatry Relat Sci 1991;28:32-41
31. Ray PG, Meador KJ, Loring DW, et al. Central anticholinergic hypersensitivity in aging. J Geriatr Psychiatry Neurol 1992;5:72-77
32. Jenkyn LR, Coffey KJ, Coffey AK, et al. Effects of antidepressants on cognitive and motor function in the elderly. Presented at the annual meeting of the American Geriatric Society; November 14-18, 1992; Washington, DC
33. Mattila MJ, Saarialho-Kere U, Mattila M. Acute effects of sertraline, amitriptyline, and placebo on the psychomotor performance of healthy subjects over 50 years of age. J Clin Psychiatry 1988;49(8, suppl):52-58
34. Cooper SM, Jackson D, Loudon JM, et al. The psychomotor effects of paroxetine alone and in combination with haloperidol, amylobarbitone, oxazepam, or alcohol. Acta Psychiatr Scand 1989;80(suppl 350):53-55
35. Hindmarch I, Shillingford J, Shillingford C. The effects of sertraline on psychomotor performance in elderly volunteers. J Clin Psychiatry 1990;51 (12,suppl B):34-36
36. Allain H, Lieury A, Brunet-Bourgin F, et al. Antidepressants and cognition: comparative effects of moclobemide, viloxazine, and maprotiline. Psychopharmacology (Berl) 1992;106(suppl):S54-S61
37. Weingartner H, Rudorfer MV, Buchsbaum MS, et al. Effects of serotonin on memory impairments. Science 1983;221:472-474
38. Martin PR, Adinoff B, Eckardt MJ, et al. Effective pharmacotherapy of alcoholic amnestic disorder with fluvoxaniinc: preliminary findings. Arch Gen Psychiatry 1989;46:617-621
39. Saletu B, Grunberger J, Anderer P, et al. Pharmacodynamics of venlafaxine evaluated by EEG brain mapping, psychometry and psychophysiology, Br J Clin Pharmacol 1992;33:589-601
40. Labrid C, Mocaer E, Kamoun A. Tianeptine. Br J Psychiatry 1992;160 (suppl 15):56-60
41. Nelson JC. Are the SSRIs really better tolerated than the TCAs for treatment of major depression? Psychiatr Ann 1994;24:628-631
42. Newhouse PA. Use of serotonin selective reuptake inhibitors in geriatric depression. J Clin Psychiatry 1996;57(suppl 5):12-22
43. Stahl SM. Serotonergic mechanisms and die new antidepressants [editorial]. Psychol Med 1993;23:281-285
44. Decker MW, McGaugh JL. The role of interactions between the cholinergic system and other neuromodulatory systems in learning and memory. Synapse 1991;7:151-168
45. Blier P, Galzin A-M, Langer SZ. Interaction between serotonin uptake inhibitors and alpha-2 adienergic heteroreceptors in the rat hypothalamus. J Pharmacol Exp Ther 1990;254:236-244
46. Costall B, Naylor RJ. The psychopharmacology of 5-HT3 receptors. Pharmacol Toxicol 1992:71:401-415
47. Leysen JE. Gaps and peculiarities in 5-HT2 receptor studies. Neuropsychopharmacology 1990;3:361-369
48. Wong DTY, Threlkeld PG, Robertson DW. Affinities of fluoxetine, its enantiomers, and other inhibitors of serotonin uptake for subtypes of serotonin receptors. Neuropsychopharmacology 1991;5:43-47
49. Jenck F, Morequ J-L, Mutel V, et al. Evidence for a role of 5-HT1c receptors in the antiserotonergic properties of some antidepressant drugs. Eur J Pharmacol 1993;231:223-229
50. Bolden-Watson C, Richelson E. Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci 1993; 52:1023-1029
51. van Harten J. Clinical pharmacokinetics of selective serotonin reuptake inhibitors. Clin Pharmacokinet 1993;24:203-220
52. Newhouse PA, Richter EM. SSRIs in depressed elderly: a double-blind comparison of sertraline and fluoxetine in depressed geriatric outpatients. Presented at the meeting of the American College of Neuropsychopharmacology; December 11-14, 1994; Puerto Rico
53. Hindmarch I, Kerr J. Behavioural toxicity of antidepressants with particular reference to moclobemide. Psychopharmacology 1992;106(suppl): S49-S55
54. Fitton A, Faulds D, Goa KL. Moclobemide: a review. Drugs. 1992;43: 561-596
55. Cesura AM, Pletscher A. The new generation of monoamine oxidase inhibitors. Fortschr Arzneimittelforschung. Prog Drug Res 1992;38: 171-297
56. Dash PK, Hochner B, Kandel ER. Injection of the cAMP-responsive element into the nucleus of Aplysia sensory neurons blocks long-term facilitation. Nature 1990;345:718-721
57. Leseh K-P, Aulakh CS, Wolozin BL, et al. Serotonin (5-HT) receptor, 5-HT transporter and G protein-effector expression: implications for depression. Pharmacol Toxicol 1992;71(suppl 1):49-60
58. Sanders-Bush E, Breeding M, Knoth K, et al. Sertraline-induced desensitization of the serotonin 5HT-2 receptor transmembrane signaling system. Psychopharmacology (Berl) 1989;99:64-69
59. Ten L, Gallagher-Thompson D. Cognitive-behavioral interventions for treatment of depression in Alzheimer's patients. Gerontologist 1991;31: 413-416